CD274 and non-small cell lung carcinoma: According to a recent study, though PFS and OS were significantly longer in the pembrolizumab-treated group than in the chemotherapy-treated group in the full NSCLC cohort with PD-L1 ≥ 1%, a clear PFS and OS benefit was only observed in the subgroup of patients with PD-L1 ≥ 50%, and higher PD-L1 expression corresponded to greater benefit (KEYNOTE 042) 12.